A glycopeptide antibiotic with diverse biological activities
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Phleomycin

Item No. 15549

Technical Information
Formal Name
(2R,3S,4S,5R,6R)-2-(((2R,3S,4S,5S,6S)-2-(2-(6-amino-2-(3-amino-1-((2,3-diamino-3-oxopropyl)amino)-3-oxopropyl)-5-methylpyrimidine-4-carboxamido)-3-((5-((1-((2-(4-((4-guanidinobutyl)carbamoyl)-4',5'-dihydro-[2,4'-bithiazol]-2'-yl)ethyl)amino)-3-hydroxy-1-oxobutan-2-yl)amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl)amino)-1-(1H-imidazol-4-yl)-3-oxopropoxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl carbamate, copper(II) salt, monohydrochloride
CAS Number
11006-33-0
Synonyms
  • PLM-D1
Molecular Formula
C55H84N20O21S2Cu • HCl
Formula Weight
Purity
≥95% (mixture of phleomycins)
A crystalline solid
PBS (pH 7.2): 10 mg/ml
λmax
242, 300 nm
SMILES
NC(CNC(CC(N)=O)C1=NC(N)=C(C(C(NC(C(NC(C(C(C)C(NC(C(NCCC2=NC(C3=NC(C(NCCCCNC(N)=N)=O)=CS3)CS2)=O)C(O)C)=O)O)C)=O)C(O[C@H]4[C@]([H])([C@H]([C@@H]([C@@H](O4)CO)O)O)O[C@H]5O[C@@H]([C@H]([C@@H]([C@@H]5O)OC(N)=O)[O-])C[O-])C6=CNC=N6)=O)=N1)C)C(N)=O.[Cu+2].Cl
InChi Code
InChI=1S/C55H84N20O21S2.ClH.Cu/c1-19-32(72-45(75-43(19)58)24(11-30(57)79)67-12-23(56)44(59)85)49(89)74-34(40(25-13-63-18-68-25)94-53-42(38(83)36(81)28(14-76)93-53)95-52-39(84)41(96-55(62)91)37(82)29(15-77)92-52)50(90)69-21(3)35(80)20(2)46(86)73-33(22(4)78)48(88)65-10-7-31-70-27(17-97-31)51-71-26(16-98-51)47(87)64-8-5-6-9-66-54(60)61;;/h13,16,18,20-24,27-29,33-42,52-53,67,76,78,80-81,83-84H,5-12,14-15,17,56H2,1-4H3,(H2,57,79)(H2,59,85)(H2,62,91)(H,63,68)(H,64,87)(H,65,88)(H,69,90)(H,73,86)(H,74,89)(H2,58,72,75)(H4,60,61,66);1H;/q-2;;+2/t20?,21?,22?,23?,24?,27?,28-,29+,33?,34?,35?,36+,37+,38-,39-,40?,41-,42-,52+,53-;;/m0../s1
InChi Key
QZGJYYBUEYHNGV-GEYAUAICSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Phleomycin is a glycopeptide antibiotic that has been found in S. verticillus and has diverse biological activities.1,2,3,4,5 It induces chromosomal breaks in S. cerevisiae when used at concentrations ranging from 1 to 2 µM.1 Phleomycin (5 or 10 µg/ml) reduces proliferation, DNA synthesis, and the percentage of cells entering mitosis in HeLa cervical cancer cells.2 In vivo, phleomycin (1 mg/kg per day), in combination with the purine analog LS34, increases survival time in an Ehrlich mouse ascites tumor model.3 It has been used as an antibiotic selection agent for successfully transformed cells in genetic engineering experiments.4,5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Moore, C.W. Internucleosomal cleavage and chromosomal degradation by bleomycin and phleomycin in yeast. Cancer Res. 48(23), 6837-6843 (1988).

    2. Kajiwara, K., Kim, U.H., and Mueller, G.C. Phleomycin, an inhibitor of replication of HeLa cells. Cancer Res. 26(2), 233-236 (1966).

    3. Allen, T.E., Brown, D.J., Cowden, W.B., et alAmplification of the antitumor activity of phleomycins in rats and mice by heterocyclic analogues of purines. J. Antibiot. (Tokyo) 37(4), 376-383 (1984).

    4. Wenzel, T.J., Migliazza, A., Steensma, H.Y., et alEfficient selection of phleomycin-resistant Saccharomyces cerevisiae transformants. Yeast 8(8), 667-668 (1992).

    5. Vickers, C.E., Bydder, S.F., and Nielsen, L.K. Dual gene expression cassette vectors with antibiotic selection markers for engineering in Saccharomyces cerevisiae. Microb. Cell Fact. 12, 96 (2013).